08 June 2021 | News
New lab will support Singapore government's Industry 4.0 agenda to build research, digital, innovation capability and talent development
Photo Credit: Cytiva
Cytiva, a global life sciences leader, opens an experience and learning lab in Singapore to strengthen the country's local biopharma ecosystem and accelerate Industry 4.0 readiness.
The new lab will contribute to Singapore's goal to be more competitive in the biopharmaceutical industry, and to drive economic growth hinged on knowledge and innovation, as outlined in Singapore's Research, Innovation and Enterprise (RIE) Plan.
Rajan Sankaran, Cytiva ASEAN General Manager, says: "We appreciate Singapore's commitment to a knowledge-based economy, and Cytiva aims to plug in as a key partner and enabler to support Singapore's ambition to be a global node of technology and innovation."
According to the Global Biopharma Resilience Index, Singapore performs strongly on new technology adaption such as AI and automation. Leveraging the new lab, Cytiva will facilitate the development of R&D and digital manufacturing talent in Singapore, in line with Singapore's national plans to reinvigorate its workforce.
Equipped with advanced process development devices, research tools, and digital technologies, the lab can provide hands-on training and download leading know-how to researchers and biomanufacturers, supporting them bringing their innovation through development and to market more efficiently and effectively.
In addition, the lab will serve as a platform for ideas exchange and access to the latest technologies in biopharma manufacturing. Cytiva plans to run 70 training programs by the end of 2021.